Daunorubicin & Cytarabine Liposome (Vyxeos™)

作者
Mallory L. Crain
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:40 (10): 30-30 被引量:17
标识
DOI:10.1097/01.cot.0000534146.30839.ec
摘要

What is daunorubicin and cytarabine liposome? Daunorubicin and cytarabine liposome is the first dual-drug liposomal encapsulation product approved by the FDA. How does this drug work? Daunorubicin inhibits DNA and RNA synthesis by forming complexes with DNA, inhibiting topoisomerase II activity, inhibiting DNA polymerase activity, affecting regulation of gene expression, and producing DNA-damaging free radicals. Cytarabine decreases DNA synthesis by inhibiting DNA polymerase. The fixed 1:5 molar ratio of daunorubicin:cytarabine was shown to be the most synergistic ratio for killing leukemia cells in vitro and in murine models. What is it approved for? Daunorubicin and cytarabine liposome is approved for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Daunorubicin and cytarabine liposome was approved based on results from an open-label, multicenter, randomized, phase III trial. Patients with newly diagnosed t-AML or AML-MRC between the ages of 60 and 75 years old were eligible for inclusion. A total of 309 patients were randomized to daunorubicin and cytarabine liposome or cytarabine and daunorubicin (7+3 or 5+2) induction and consolidation. The complete remission rate was higher with daunorubicin and cytarabine liposome (38% vs. 26%, p=0.036). Median event-free survival (2.5 vs. 1.3 months, p=0.021) and overall survival (9.6 vs. 5.9 months, p=0.005) were significantly better in patients who received daunorubicin and cytarabine liposome (J Clin Oncol 2016;34:15_suppl.7000). How do you administer this drug? Induction with daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 liposome is given intravenously over 90 minutes on days 1, 3, and 5. If second induction is needed, the same dose is given on days 1 and 3. Daunorubicin 29 mg/m2 and cytarabine 65 m/m2 liposome is given on days 1 and 3 for up to 2 cycles of consolidation. Are there any premedications needed for daunorubicin and cytarabine liposome? Prophylactic antiemetics, such as ondansetron and dexamethasone, should be administered prior to daunorubicin and cytarabine liposome since this medication has a moderate emetic risk. What are side effects associated with daunorubicin and cytarabine liposome (≥ 10%)? Side effects more commonly observed with daunorubicin and cytarabine liposome included (≥ 5% over control arm): Hematologic: hemorrhage, prolonged thrombocytopenia, prolonged neutropenia Infections: fungal, upper respiratory, catheter/device/injection site Other: rash, pruritus, cough, headache, visual impairment What are some other side effects? Patients may develop cardiotoxicity, hypersensitivity reactions, and tissue necrosis. Before administering daunorubicin and cytarabine liposome, the patient's cumulative anthracycline exposure should be calculated and assessed for appropriateness. Since daunorubicin and cytarabine liposome contains copper gluconate, copper overload may also occur. Are there any important drug interactions? Monitor cardiac and hepatic function at baseline and when used with other cardiotoxic and hepatotoxic agents, respectively. How do I adjust the dose in the setting of renal or hepatic insufficiency? Dose adjustments are not required for renal or hepatic insufficiency. Daunorubicin and cytarabine liposome is metabolized in the liver and excreted renally, but has not been studied in patients with severe renal impairment/end-stage renal disease or bilirubin levels greater than 3 mg/dL. Practical tips: If patients develop a hypersensitivity reaction, premedicate patients with an antihistamine and/or corticosteroid prior to subsequent doses. Do not interchange daunorubicin and cytarabine liposome with other daunorubicin and/or cytarabine products. Daunorubicin and cytarabine liposome has unique preparation instructions that pharmacy staff should be trained on. The total preparation time takes close to an hour with key steps including equilibration to room temperature, reconstitution followed by swirling vial contents, and aseptically transferring the medication to an infusion bag. What should my patients know? Patients should be educated on the administration schedule of daunorubicin and cytarabine liposome, as well as side effects, and contact their health care provider if they develop a hypersensitivity reaction, uncontrolled nausea or vomiting, or fever or chills. Side effects that patients should be educated on include low blood counts, increased risk of infection, hypersensitivity reactions, and cardiotoxicity. What else should I know? Daunorubicin and cytarabine liposome should only be used in patients with t-AML or AML-MRC. Patients who received daunorubicin and cytarabine liposome had more prolonged thrombocytopenia and neutropenia leading to increased infections and hemorrhage. Daunorubicin and cytarabine liposome has unique preparation instructions and should not be interchanged with other daunorubicin and/or cytarabine products. What useful links are available? https://vyxeos.com/ https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm Any ongoing clinical trials related to daunorubicin and cytarabine liposome? Multiple clinical trials with daunorubicin and cytarabine liposome are ongoing including trials in adult patients with newly diagnosed, relapsed/refractory AML, and myelodysplastic syndromes as well as exploration of use in the pediatric population. More can be found at https://clinicaltrials.gov. MALLORY L. CRAIN, PHARMD, is PGY2 Oncology Resident, Department of Pharmacy at Barnes-Jewish Hospital, St. Louis, Mo. RAMASWAMY GOVINDAN, MD, Professor of Medicine; Anheuser Busch Chair in Medical Oncology; and Director, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine, serves as the Pharmacy Forum column physician advisor.Mallory L. Crain, PharmD: Mallory L. Crain, PharmDRamaswamy Govindan, MD: Ramaswamy Govindan, MD

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
文艺紫菜发布了新的文献求助10
1秒前
kinsley完成签到,获得积分10
1秒前
1秒前
Lucas的应助被punch采纳,获得10
1秒前
傢誠发布了新的文献求助10
1秒前
1秒前
快乐的鱼发布了新的文献求助10
2秒前
orixero的应助被zhz采纳,获得10
2秒前
2秒前
zz发布了新的文献求助10
3秒前
所所的应助被PEITON采纳,获得10
4秒前
jun完成签到,获得积分10
4秒前
qiaobbbbb发布了新的文献求助10
5秒前
章绝施发布了新的文献求助10
5秒前
cc发布了新的文献求助10
5秒前
66666发布了新的文献求助30
5秒前
5秒前
petrichor完成签到,获得积分10
6秒前
charles完成签到,获得积分10
7秒前
星辰大海的应助被123采纳,获得10
7秒前
7秒前
SciGPT的应助被平凡的一天采纳,获得10
7秒前
纯真的梦竹完成签到,获得积分10
8秒前
kinsley发布了新的文献求助10
9秒前
9秒前
Merkuro发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
爆米花的应助被charles采纳,获得10
10秒前
10秒前
11秒前
Litchi完成签到 ,获得积分10
11秒前
倾枝发布了新的文献求助10
12秒前
12秒前
钟爱小奏完成签到,获得积分10
13秒前
PP发布了新的文献求助10
13秒前
Akim的应助被香香香采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952